Stockscreener 앱 받기
26.98
1.16%
0.31
시간 외 거래:
26.98
전일 마감가:
$26.67
열려 있는:
$26.26
하루 거래량:
959.59K
Relative Volume:
0.80
시가총액:
$3.23B
수익:
$22.57M
순이익/손실:
$-212.73M
주가수익비율:
-14.95
EPS:
-1.8045
순현금흐름:
$-142.19M
1주 성능:
-3.51%
1개월 성능:
-18.95%
6개월 성능:
-22.09%
1년 성능:
+7.19%
1일 변동 폭
$26.01
$27.06
1주일 범위
$26.01
$28.97
52주 변동 폭
$23.05
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
26.98 | 3.33B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB - marketbeat.com
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan
NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer - Stock Titan
Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative? - webull.com
How Newamsterdam Pharma Company N.v. (NAMS) Affects Rotational Strategy Timing - Stock Traders Daily
HC Wainwright Issues Pessimistic Outlook for NAMS Earnings - marketbeat.com
Equities Analysts Offer Predictions for NAMS FY2027 Earnings - marketbeat.com
NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires - Bitget
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
(NAMSW) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake - Stock Titan
Three New Hires Receive Stock Awards With Up to 4-Year Vesting - Stock Titan
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - The Manila Times
NewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingView
NewAmsterdam Pharma Co N.V. Q2 2026: Revenue $3.7M, EPS $(0.52) — 10-Q Summary - TradingView
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - 富途牛牛
NAMS Q2'26 Earnings: revenue estimate is 1.88M USD - TradingView
NewAmsterdam Pharma (Nasdaq: NAMS) June-quarter loss widens; cash $678M - Stock Titan
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring An 86.77% Upside Potential - DirectorsTalk Interviews
NewAmsterdam Pharma Q1 2026 Earnings: EPS Beat Narrower Than Expected, Stock Edges DownBuyback Announcement Report - dars.gov.et
(NAMS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP - marketbeat.com
NewAmsterdam Pharma to Host Investor Day on August 5, 2026 - GlobeNewswire
NewAmsterdam Pharma Warrants (NAMSW) Decline 6.58% as Selling Pressure MountsVWAP Breakout - dars.gov.et
Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - marketbeat.com
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NAMS|NewAmsterdam Pharma Company NV|Price:30.190|Chg%:+0.550 - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Income Statement - TradingKey
TradingKey - TradingKey
NewAmsterdam Pharma says EU CHMP backs approval of Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Cash Flow - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill - Seeking Alpha
NAMS|NewAmsterdam Pharma Company NV|Price:29.640|Chg%:-0.910 - TradingKey
NewAmsterdam says EU CHMP backs Ubeslo, Evlarco cholesterol drugs for approval - Bitget
NewAmsterdam Pharma (NAMS) Slides 2.98% as Biotech Sector Faces HeadwindsNews Sentiment - dars.gov.et
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26 - TradingView
NewAmsterdam Pharma and Menarini Group Receive Positive - GlobeNewswire
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):